- Home
- CHRS vs CCRD Comparison
CHRS vs CCRD Comparison
Compare CHRS & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CCRD
- Stock Information
- Founded
- CHRS 2010
- CCRD 1973
- Country
- CHRS United States
- CCRD United States
- Employees
- CHRS N/A
- CCRD N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CCRD
- Sector
- CHRS Health Care
- CCRD
- Exchange
- CHRS Nasdaq
- CCRD Nasdaq
- Market Cap
- CHRS 84.2M
- CCRD 157.9M
- IPO Year
- CHRS 2014
- CCRD N/A
- Fundamental
- Price
- CHRS $0.75
- CCRD $29.55
- Analyst Decision
- CHRS Buy
- CCRD Hold
- Analyst Count
- CHRS 3
- CCRD 1
- Target Price
- CHRS $4.68
- CCRD $21.00
- AVG Volume (30 Days)
- CHRS 1.3M
- CCRD 114.5K
- Earning Date
- CHRS 08-07-2025
- CCRD 07-31-2025
- Dividend Yield
- CHRS N/A
- CCRD N/A
- EPS Growth
- CHRS N/A
- CCRD 187.14
- EPS
- CHRS N/A
- CCRD 0.86
- Revenue
- CHRS $272,251,000.00
- CCRD $61,011,000.00
- Revenue This Year
- CHRS N/A
- CCRD $17.35
- Revenue Next Year
- CHRS $106.56
- CCRD N/A
- P/E Ratio
- CHRS N/A
- CCRD $33.51
- Revenue Growth
- CHRS 19.87
- CCRD 12.31
- 52 Week Low
- CHRS $0.66
- CCRD $11.57
- 52 Week High
- CHRS $2.43
- CCRD $31.99
- Technical
- Relative Strength Index (RSI)
- CHRS 44.78
- CCRD 63.89
- Support Level
- CHRS $0.72
- CCRD $28.50
- Resistance Level
- CHRS $0.82
- CCRD $29.88
- Average True Range (ATR)
- CHRS 0.04
- CCRD 1.06
- MACD
- CHRS 0.01
- CCRD -0.19
- Stochastic Oscillator
- CHRS 33.21
- CCRD 84.71
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.